Vistagen Therapeutics (NASDAQ: VTGN) is one of 497 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Vistagen Therapeutics to related businesses based on the strength of its profitability, institutional ownership, dividends, risk, valuation, analyst recommendations and earnings.
Volatility and Risk
Vistagen Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Vistagen Therapeutics’ peers have a beta of 1.10, indicating that their average share price is 10% more volatile than the S&P 500.
Institutional & Insider Ownership
9.4% of Vistagen Therapeutics shares are held by institutional investors. Comparatively, 47.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 16.1% of Vistagen Therapeutics shares are held by insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings for Vistagen Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vistagen Therapeutics Competitors||3132||9479||22583||682||2.58|
Vistagen Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 629.93%. As a group, “Pharmaceutical preparations” companies have a potential upside of 41.27%. Given Vistagen Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Vistagen Therapeutics is more favorable than its peers.
This table compares Vistagen Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vistagen Therapeutics Competitors||-2,968.95%||-161.14%||-30.85%|
Valuation and Earnings
This table compares Vistagen Therapeutics and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Vistagen Therapeutics||$1.25 million||-$10.25 million||-1.23|
|Vistagen Therapeutics Competitors||$2.00 billion||$130.71 million||-3.07|
Vistagen Therapeutics’ peers have higher revenue and earnings than Vistagen Therapeutics. Vistagen Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Vistagen Therapeutics peers beat Vistagen Therapeutics on 7 of the 13 factors compared.
Vistagen Therapeutics Company Profile
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells. In addition, the company develops CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. VistaGen Therapeutics, Inc. has licensing, sublicensing, and collaboration agreements with BlueRock Therapeutics, LP; U.S. National Institutes of Health; Cato Research Ltd.; and University Health Network. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.